{"page_content": "A Healthy Amgen\n62  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nIntroduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix\nGUARDING AGAINST COUNTERFEIT MEDICINES \nAmgen takes the issue of counterfeit drugs very seriously and \napplies significant efforts to deter, detect, and disrupt criminal \ncounterfeiting of our medicines, includingSUPPLIER COMPLIANCE \nExternal service providers, component suppliers, and \ncontract manufacturers play an increasingly important \npart in Amgen\u2019s manufacturing strategy  . Their operational \nperformance and compliance with applicable regulations \nhave direct impact on the quality of Amgen final drug \nand combination products  . Because of this, we audit the \noperations of our suppliers to help ensure the products \nthey manufacture or services they provide meet Amgen\u2019s \nand regulators\u2019 expectations for quality  . We have formal \nprograms to continuously monitor the performance and \nprovide oversight and support for our suppliers  . \nMORE INFORMATION  \nGlobal Patient Safety \nAbout Amgen Clinical Trials\nAdverse Event and Product Complaint Reporting\nQuality Assurance of Our Medicines\nEmploying sophisticated technology to hamper the \nability of counterfeiters to create packaging that \nresembles Amgen\u2019s packaging  .\nIn the United States, requiring wholesalers to buy only \ndirectly from Amgen, and auditing compliance with \nthese purchasing practices  .\nPartnering with federal and state law enforcement \nagencies to investigate and prosecute those involved \nin product tampering and counterfeiting, facilitating \nthe arrest and conviction of counterfeiters  .\nIn addition, Amgen uses industry-leading serialization and \ntraceability technologies where required to advance the \nsecurity of the supply chain and protect our products and \npatients  . Amgen products have distinctive security features \nthat allow us to confirm whether a product has been legitimately \nproduced following Amgen quality standards  . \nFor more information, see our counterfeit drug statement . PATIENT SAFETY & \nPRODUCT QUALITY", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 61, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}